Literature DB >> 19997693

Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006.

Jaw-Shyang Jih1, Yi-Ju Chen, Ming-Wei Lin, Yu-Chun Chen, Tzeng-Ji Chen, Yu-Lin Huang, Chih-Chiang Chen, Ding-Dar Lee, Yun-Ting Chang, Wen-Jen Wang, Han-Nan Liu.   

Abstract

To analyse the epidemiological characteristics and related costs of herpes zoster in Taiwan, a nationally representative cohort of 1,000,000 individuals from the National Health Insurance register was followed up from 2000 to 2006 and their claims data analysed. Overall, 34,280 patients were diagnosed with zoster (incidence 4.89/1000 person-years) and 2944 patients (8.6%) developed post-herpetic neuralgia 3 months after the start of the zoster rash (incidence 0.42/1000 person-years). People with older age, diabetes, and immunocompromising conditions were at higher risk of developing zoster and post-herpetic neuralgia. The overall hospitalization rate for zoster was 16.1 cases per 100,000 person-years. The cost for each home care case and per hospitalized case were approximately 53.30 euro and 1224.70 euro, respectively. Further research into the cost-effectiveness of zoster vaccine is needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19997693     DOI: 10.2340/00015555-0729

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  41 in total

Review 1.  Epidemiology of neuropathic pain and its impact on quality of life.

Authors:  Blair H Smith; Nicola Torrance
Journal:  Curr Pain Headache Rep       Date:  2012-06

Review 2.  Evaluation of the economic burden of Herpes Zoster (HZ) infection.

Authors:  Donatella Panatto; Nicola Luigi Bragazzi; Emanuela Rizzitelli; Paolo Bonanni; Sara Boccalini; Giancarlo Icardi; Roberto Gasparini; Daniela Amicizia
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer.

Authors:  Ian H Frazer; Myron J Levin
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

4.  Statins can increase the risk of herpes zoster infection in Asia.

Authors:  H-H Chen; C-L Lin; C-J Yeh; S-Y Yeh; C-H Kao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-12       Impact factor: 3.267

5.  The case for Zostavax vaccination in systemic lupus erythematosus.

Authors:  Abigail R Cogman; Eliza F Chakravarty
Journal:  Vaccine       Date:  2013-06-03       Impact factor: 3.641

Review 6.  Topical analgesics for neuropathic pain in the elderly: current and future prospects.

Authors:  Jana Sawynok
Journal:  Drugs Aging       Date:  2014-12       Impact factor: 3.923

7.  Risk of cancer among patients with herpes zoster infection: a population-based study.

Authors:  Yu-Ping Wang; Chia-Jen Liu; Yu-Wen Hu; Tzeng-Ji Chen; Yi-Tsung Lin; Chang-Phone Fung
Journal:  CMAJ       Date:  2012-09-17       Impact factor: 8.262

Review 8.  Vaccines for preventing herpes zoster in older adults.

Authors:  Anna M Z Gagliardi; Brenda N G Andriolo; Maria R Torloni; Bernardo G O Soares
Journal:  Cochrane Database Syst Rev       Date:  2016-03-03

Review 9.  Sex differences in the incidence of skin and skin-related diseases in Olmsted County, Minnesota, United States, and a comparison with other rates published worldwide.

Authors:  Louise K Andersen; Mark D P Davis
Journal:  Int J Dermatol       Date:  2016-03-24       Impact factor: 2.736

10.  A systematic literature review of herpes zoster incidence worldwide.

Authors:  Désirée van Oorschot; Hilde Vroling; Eveline Bunge; John Diaz-Decaro; Desmond Curran; Barbara Yawn
Journal:  Hum Vaccin Immunother       Date:  2021-03-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.